this joining morning. Thanks, Hello, us thanks and Kyle. for everyone,
comparable growth We've made our on of reported profitable X% X. Slide on on second In sustainable quarter, progress We had of an a tremendous and start year-over-year growth. we XXXX. X integration Let's and for on first of exciting the XX% basis. plans delivered Lima delivered the months
accomplishments year. improvements we've for from XXX EBITDA margins basis of pleased XXXX the that Recon, second mix reflecting a with in we are change Lima. set impact the expanded first our ourselves of step confident strong and of a half half points, We are adjusted and the Overall, by our productivity up
X, about delivered basis revenue integration-related growth. Slide or grew a estimated we on X% when synergies. XX% impacts planned global XX% for Recon In Recon quarter comparable on adjusting the reported in from
continue including and our directly We X%, in In impacts see overlapping U.S. X% grew the integration-related U.S. in Business. U.S. growth of quarter, Hips Recon and Extremities majority to Recon X% Knees. in the
U.S. these are typical growth growth the our understood numbers are levels, and While well below well causes temporary.
on to day issues. the international continue closing while resilient progress to gotten since a X, On no grew Since our on made acquisition a the plans. we in integration integration want start X. XX% we activities to our In major update markets, we've execute January Slide X, market with unforeseen have you Lima the I strong off
significant progress a as detailed us achieved player. have We premier orthopedics have position plan global that high-growth a developed multiyear and will
first commercial over been we've the acquisitions, from laser-focused channels As prior we've months learned our aligned. getting X
Our always drive to terrific to the put quickly teams do to goal long-term made and place strategy been term and and progress in our has proven move execute We've disruption here. a growth. processes sustainable short
are markets been international force ] XX% sales about solidified under [ legacy structure has ENOVA U.S. our Our complete. and
exciting second track of will and revenue as overall as We ahead dissynergies continues the move our Our moderate of [ opportunities. the we estimates. cross-selling QX expected peaked associated realizing to into believe with in and ] acquisition slightly the start some original half
of of to million to expect comfortably be $XX guidance $XX negative our With progress the we've range revenue impact. million within initial made we
plan Our similarly on track. value on is side creation cost the
footprint support XX% global years manufacturing X This of and represents Lima functions, from Our something comes believe and cost within $XX our synergy scale about million we revenues, achievable. legacy duplicative is business significant of targets improving but leveraging processes. eliminating
and an to have plans eye investment accelerating long key with near in the commercial term opportunities impact in teams and programs. R&D any these attack diligent towards Our minimizing
dig We'll U.S. into performance our growth X. Recon Slide on deeper
and to slower plan through a have are clear expected several growth We as accelerate. quarters but path passing
to earlier, the to half and As growth the X% estimated outlined impact of the business U.S. we knee X% first Recon integration-related across felt hips, most in shoulder. about be of dissynergies
and Looking in at divergence said, from believe X% consolidation. strong very business, year our our remain our comparison despite a market or start U.S. ] the and headwinds trend more. year-to-date channel growth USM knee XX% from hip per year the is of growth historical levels of above we rates prior That [
further and [ continued enables have nice expect to to and our growth ] into as grow a in surgeon Cones continues knee revision harvest We half base our acceleration penetration launch second the ramp.
hip pressure U.S. hips around product integration in needs. stem direct couple of offset headwinds designs between drive to sustained trend addressing in in year-end time include foot the with U.S. the and impacts, quarters, shift address some cycles system our ankle that a beyond. launched growth be been at impaction XXXX in anterior has we temporary and that to new business last have a Lima These are products by are Extremities market the double-digit new several of to growth under addition expected accelerating shifting been business. our surgical the to procedures.
In strong and We're shoulder
overlap the is saw thus half. Shoulder channel the through with and segment the As first a the of Lima felt direct reminder, with U.S. brunt we disruption the most
a per QX, We in which a use addresses outcomes the of in been revenue significant our cases be technology for has of for to creating and also on also will for increase and launch augments the surgeons Altivate Arvis shoulder, balance already controlled a a lot in year. with used product the This Reverse We're Augmented Glenoid procedure. desire cases complex growing positive better launching has key from energy have the system.
workflow, growth or procedures to strong of as bring shoulder cost for creating above-market our Arvis the seamlessly innovation-driven with robotic procedural great leader connect limitation the will These shoulder. surgeons products opportunity new will a their reestablish repeatable solutions. the without time opportunity large planning in
ankle market across into built our levels and sustain with foot innovation normal innovations Overall, well we're we've newly the to year. the to the continue to we're the the channel And can market we as about accelerate strong aligned anatomies to above in our excited coming back our our growth we second half. more confident exit channel, that growth. Finally, we feed
Turning on to P&R Slide X.
Our disciplined X% comparable reflects growth a market execution. environment stable and
positions. reading portfolio and continue mix. We higher to consistent drive value portfolios improved improve P&R improving as margin work year-over-year XX higher innovations points bracing improvements both adjusted and leverage our the EGX segments. market-leading Sciences on growth, This to our new we tools shifting and continue is to EBITDA as portfolio through to strengthening by in doing and launching this basis productivity Recovery We're
small work unprofitable I'm which as we we're million portfolio, we set shape impacted of performance, the growth half. assets half in confident up Additionally, the to in off and XXXX by quarter. sold $X first I'm to profitability and and business, accelerate the Overall, pleased our exited sales with a second
you Now details. I'll let through take the P&L Ben? Ben